Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MERMAID-2: durvalumab versus placebo for MRD-positive stage II to III NSCLC after curative therapy

Phase 3 trial of adjuvant durvalumab versus placebo in patients with resected stage II to III non-small cell lung cancer who become MRD-positive during surveillance without RECIST recurrence. ClinicalTrials.gov lists the study as completed.

AstraZeneca